pathway plays an important role in the antioxidative and antiapoptotic effects of GLP-1 receptor activation in the heart is not known. In this study, we investigated the mechanistic effects of exendin-4 (GLP-1 receptor agonist) and its signaling on the prevention of oxidative stress and apoptosis. Methods: Intracellular reactive oxygen species (ROS) level was measured using 2,7-dichlorofluorescin diacetate (DCF-DA). The mRNA expression of antioxidative genes and antiapoptotic genes were assessed by RT-qPCR. Apoptotic cells were detected by TUNEL assay. Results: Exendin-4 significantly inhibited H2O2-induced ROS production. The antioxidant activity of exendin-4 was inhibited by a GLP-1 receptor antagonist and an adenylyl cyclase inhibitor. The decrease in ROS production by exendin-4 was not affected by PKI, a PKA inhibitor, (Fig. 1) whereas the depletion of Epac by siRNA strongly inhibited exendin-4-mediated antioxidation (Fig. 2) . Moreover, exendin-4 induced mRNA expression of antioxidant genes, including catalase and MnSOD. GLP-1 receptor activation by exendin-4 also suppressed H2O2-induced apoptosis. Treatment with exendin-4 increased mRNA expression levels of antiapoptotic genes, including Bcl-2 and Bcl-xL. The antiapoptotic effect of exendin-4 was abolished by pretreatment with either PKA inhibitor or Epac siRNA.
Background: A chronic NO deficiency occurs under several physiological and pathophysiological conditions. The reduction in NOS activity during heart failure must also be considered, such as the reduced NO levels in chronic renal insufficiency. On the other hand, a chronic decrease in NO is considered responsible for a variety of cardiovascular diseases. There is evidence that chronic NO deficiency contributes to increased matrix deposition and fibrosis. The current study investigates to what extent a chronic deficiency in nitric oxide affects the structural and functional remodeling of the left (LV) and right (RV) ventricle. Methods: NO deficit was achieved in adult rats by feeding them the NO-synthaseinhibitor L-NAME alone (L) and in combination with captopril (L/C) or tempol (L/T) (n=8 each group). Heart weight to body weight ratio, the expression of fibrotic and hypertrophic genes (RT-PCR, Western Blot) as well as the cardiac function (Millar Tip-catheter) and the postmortal ventricular geometry were determined after four weeks. Results: No changes occurred in any parameters in the LV independent of the treatment scheme. In contrast, RV of the L group displayed a significant increase in TGFβ (+94%) and collagen (+80%) expression and displayed anatomical and functional features of a restrictive cardiomyopathy. These changes could be prevented by additional feeding of captopril (L/C) or tempol (L/T). In isolated cardiomyocytes of untreated rats L-NAME treatment led to an increased ROS production (+49%) which could be blocked by preincubation with captopril. The observation that only RV was affected by this mechanism could be explained by a different expression pattern of superoxid dismutases (SOD). However, in contrast to a significant upregulation of SOD2 in the left ventricle of L-NAME fed animals, even a decrease of SOD2 expression took place in the RV. Conlusion: Increased levels of ROS are responsible for the negative remodeling of right ventricles in chronic NO deficient rats. The cardioprotective effects of captopril and tempol are mediated through a normalization of ROS levels independent of blood pressure reducing effects.
Abstract P5041 - Purpose: Hypertension induces cardiac remodelling at the structural and functional level. Endothelin-1 (ET-1) may contribute to cardiac remodelling. It is not known, however, whether atrial ET-1 signalling is altered in hypertension. Here we tested the hypothesis that ET-1 signalling is augmented in the atria of spontaneously hypertensive rats (SHR) and that this may contribute to hypertensioninduced atrial arrhythmias. Methods: SHR and control Wistar-Kyoto (WKY) rats were studied at 6-8 months of age. Hearts were removed for morphometric analysis. Atria were snap frozen and analyzed for mRNA and protein expression by qPCR and Western blotting. Isolated atrial myocytes were field stimulated in the presence of 50 nM ET-1, and Ca transients (CaTs) were characterized at the global or subcellular level by epifluorescence (Fura-2/AM) and line scan confocal microscopy (Fluo-4/AM). To mimic atrial tachycardia, atrial tissue slices were stimulated at 5 Hz for up to 20 h and used for Western blotting. Results: At 6-8 months of age, SHR exhibited compensated LV hypertrophy, but left atrial hypotrophy, despite increased atrial mRNA levels of BNP (2-fold) and β-MHC (3.6-fold), while α-MHC was unaffected. There were no differences in global CaTs between atrial myocytes from WKY and SHR. Exposure of atrial myocytes to 50 nM ET-1 caused a 35% increase in systolic Ca in SHR (n=14), but only a 16% increase in WKY (n=21; P<0.05). Moreover, in SHR atrial myocytes, ET-1 induced a larger fractional SR Ca release (P<0.05 vs WKY). The ET-1-induced increase in CaTs occurred in the subsarcolemmal as well as in the central cytoplasm. Notably, ET-1 also induced arrhythmogenic Ca waves both in SHR and WKY atrial myocytes. Further analysis at the molecular level indicated that the atrial mRNA expression of ET-1 was increased (2-fold) in SHR. ETA receptor expression was unaltered at the mRNA level but upregulated (4-fold) at the protein level in the left atria. Gαq and PLCβ (isoforms 1 and 4) mRNA expression were also upregulated in SHR. Simulated atrial tachycardia in atrial tissue slices caused a 2-fold upregulation of ETA receptor expression in both SHR and WKY. Conclusions: At 6-8 months, SHR exhibit increased atrial expression of ET-1, ETA receptors, Gαq and PLCβ. Atrial tachycardia further increases ETA receptor expression. At the functional level, atrial myocytes from SHR respond to ET-1 with increases in systolic Ca and the development of arrhythmogenic Ca waves. Thus, atrial ET-1 signalling is enhanced already at early stages of hypertension and may contribute to the initiation of atrial tachycardia in hypertension. Background: Chronic inflammation in the atrial myocardium plays an important role in the development of atrial fibrosis in Atrial Fibrillation (AF). However, it is not clear whether atrial inflammatory reaction is associated with inflammation in ventricular myocardium. Our aim was to assess the extent of fibrosis and inflammatory reaction in human ventricular myocardium and explore its association with AF. Methods: Medical records from consecutive autopsies were checked for AF history. Heart specimens from 30 patients who died from cardiovascular causes (64±12 y, 17 men) were collected in two predefined groups: with AF history (n=20) and without (n=10). Tissue samples were taken from the Bachmann Bundle (BB), Left (LV) and Right (RV) ventricle free walls and stained with Masson's trichrome for analysis of fibrosis extent. Immunohistochemistry was performed using CD3-and CD45-antigen antibodies and quantified as number of antigenpositive cells per 1 mm 2 . Results: There were no differences between the groups in regard to age or comorbidities expressed as CHA2DS2-VASc scores (Table) . Fibrosis extent, CD3+ and CD45+ immune cell counts were elevated in AF patients regardless of tissue sampling location (Table) . Fibrosis extent correlated with both CD3+ (r=0.73, p<0.001 for RV; r=0.40, p=0.028 for LV) and CD45+ (r=0.75, p<0.001 for RV; r=0.49, p=0.006 for LV) cell counts. Fibrosis at BB correlated with RV (r=0.57, p=0.001) but not with LV (r=0.27, p=0.14). Neither fibrosis extent nor inflammatory cell count showed any correlation with either age or comorbidities.
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Conclusion:
Histological signs of chronic inflammation affecting ventricular myocardium are strongly associated with AF and demonstrate significant correlation with fibrosis extent that cannot be explained by cardiovascular comorbidities otherwise. Since histologic markers of fibrosis and inflammation are not confined to atrial myocardium, AF could be the cause or consequence of diffuse myocardial insult on the entire heart that requires further studies. Purpose: Heart failure is one of the most prevalent causes of death in the western world. Caveolin1 knockout mice (cav1-/-) develop a severe hypertrophic cardiomyopathy with functional impairment especially in cardiac output and ejection fraction. Behavior observation during the breeding of this mouse line revealed, that the animals showed a markedly reduced activity. Physiological inactivity can also contribute to heart diseases. The aim of the current study was to test, if moderate physical activity (swim training) can improve heart function and reverse cardiac morphological alterations in this particular model. The efficiency of training was unclear, because caveolin-1 deficiency is associated with eNOS hyperactivation. Hyperactivation of eNOS can lead to massive radical production. Overexpression of eNOS has been described to be counteracting the beneficial effects of training with respect to improved cardiovascular function. Methods and results: Echocardiographic measurements of 8 week old animals show that cav1-/-mice had an increased left ventricular posterior wall thickness resulting in a reduced left ventricular volume. Previous data from our group have demonstrated that this left ventricular hypertrophy leads to a reduced cardiac function (reduced stroke volume and cardiac output) in older mice combined with reduced physical ability in swimming tests compared to wild type mice. Six weeks of moderate training (2 weeks 5 min/day, 2 weeks 10 min/day and 2 weeks 15 min/day) resulted in markedly prolonged swim duration (untrained: 11±4 min vs. training: 50±12 min) in cav1-/-mice. In line with this, the functional parameters following training showed that stroke volume and cardiac output (measured by echocardiography) were comparable to wild type littermates. Furthermore, the left ventricular wall thickness was reduced in during the training period leading to a significantly higher intraventricular volume. None the less, heart and lung weight of these animals were still significantly elevated. Conclusions: In conclusion the present study documents that moderate training can inhibit the progression of heart failure in a hypertrophic mouse model with elevated eNOS activity. It remains to be established, if the beneficial effects are mediated by direct cardiac mechanisms, or if alterations in the peripheral circulation e.g. in blood viscosity or in peripheral resistance are involved here.
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The role of TIMP3 in the development of myocardial fatty accumulation and lipid handling (Timp3), a potent inhibitor of MMP's, in the development of dysfunctional metabolic handling of lipids and intramyocardial lipid accumulation. In previous research we observed increased atherosclerosis (p<0.01) in Apoe-/-Timp3-/-(ET3KO) mice compared to ApoE-/-(EKO) mice. Aortic root analysis revealed increased lesion area, higher lipid deposition, increased necrotic core and F4/80 positive cell infiltration in ETKO mice. Cholesterol and Triglycerides were not significantly altered, while fasting hypoglycaemia was evident (P<0.0002). Methods: We investigated the role of Timp3 through the use of Metabolomics, RNA and protein expression as well as histologic analyses, between EKO and ET3KO mice. LAD ligation was performed to investigate its role during myocardial ischaemia. Results: Metabolomic analysis of the serum showed dysfunctional metabolic handling of fatty acids (FA) as evidenced by reductions in long-chain monounsaturated fatty acids (MUFA) such as 10-nonadecenoate and 10-heptadecenoate, medium-chain acyl-carnitines (e.g., hexanoylcarnitine), medium-chain acylglycine (i.e., valerylglycine) and the medium-chain fatty acid marker of betaoxidation, 3-hydroxydecanoate. The long-chain acyl-carnitine stearoylcarnitine was elevated. A depletion of the antioxidant, ergothioneine, and a liver-modified form of a soy-derived phytoestrogen, equol sulfate, indicated a loss of antioxidant and anti-inflammatory chemicals in ET3KO. Markers of insulin resistance such as 2-hydroxybutyrate and 2-aminobutyrate were also increased. The reduction of SCD-1, as suggested by the metabolomics data, was confirmed at RNA level in the heart of ET3KO mice. Histological analysis of the ET3KO hearts showed increased intramyocardial lipid deposition as well as areas of extensive fibrosis. Hearts showed reduced levels of PPAR-alpha suggesting an inability to handle lipids (P<0.05 for both). LAD ligation to investigate defective FA oxidation and its impact in the setting of acute ischaemia showed increased peri-operative mortality was in the ET3KO group (13 out of 19 vs 2 out of 13 p< 0.005) with no apparent bleeding or other cause being identified suggesting an inability of these hearts to withstand ischaemia and its acute change in metabolic demand. Conclusion: Our data suggests that TIMP3 loss on the background of EKO leads to an inability of the heart to handle lipids leading to the accumulation of intramyocardial lipids and finally resulting in fibrosis and an inability to handle the acute metabolic switch during ischaemia.
